Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1984 • 714 citations

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1988 • 703 citations

B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.

1983 • 517 citations

A clinical trial of anti-idiotype therapy for B cell malignancy

1985 • 434 citations

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.

1980 • 413 citations

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1989 • 356 citations

Redesigning Nature's Poisons to Create Anti-Tumor Reagents

1987 • 329 citations

Serotherapy of acute lymphoblastic leukemia with monoclonal antibody

1981 • 324 citations

Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma

1983 • 277 citations

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.

1991 • 231 citations

Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.

1987 • 212 citations

Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution.

1982 • 200 citations

Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody.

1984 • 175 citations

Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia

1984 • 166 citations

Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2

1988 • 164 citations

Targeted Toxin Therapy for the Treatment of Cancer

1989 • 158 citations

Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies

1989 • 124 citations

Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.

1989 • 122 citations

Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T- cell lymphoma

1991 • 118 citations

An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.

1991 • 117 citations

Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.

1988 • 116 citations

Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid- resistant acute graft-versus-host disease

1990 • 105 citations

A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.

1990 • 92 citations

Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.

1989 • 88 citations

The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides

1991 • 85 citations

Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia

1983 • 78 citations

An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensin

1989 • 64 citations

Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis

1989 • 60 citations

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.

1990 • 52 citations

Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow

1987 • 52 citations

Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function

1989 • 34 citations

Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins.

1985 • 21 citations

Therapy of metastatic malignant melanoma using xomazyme® Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin

1989 • 15 citations